AI Article Synopsis
- Pandrug-resistant (PDR) bacterial infections lead to longer hospital stays and increased mortality, with a study assessing 30 patients over three years examining treatment options.
- The most common PDR bacteria identified were Acinetobacter baumannii (63.3%), Klebsiella pneumoniae (20.0%), and Pseudomonas aeruginosa (16.7%), with clinical pharmacists recommending effective treatment regimens achieving an 82.8% clinical cure rate.
- Combination therapy involving doxycycline was found to be the most effective in treating PDR infections, with significant success rates in both monotherapy and combination therapy cases.
Article Abstract
Objective: Pandrug-resistant (PDR) bacterial infections are associated with considerable prolongation of hospitalization and mortality in clinical practice.
Method: This case-series study was conducted during a 3-year period from 2011 to 2013. A total of 30 PDR patients consulted by clinical pharmacist were recorded to evaluate the anti-infection treatment.
Results: All isolates of PDR bacteria from patients were identified as pan-drug resistant acine-tobacter baumannii (63.3%), pan-drug resistant klebsiella pneumonia (20.0%), and pandrug-resistant pseudomonas aeruginosa (16.7%). Of the 30 patients, 96.7% therapeutic regimens supposed by clinical pharmacists were applied to treat the infectious patients up to 82.8% clinical cure rates. 30 patients completed the prescribed treatment, of which 19 underwent monotherapy that the clinical cure rate was 78.9%, and 10 underwent combination therapy that the clinical cure rate was 90.0%. In the following therapy, doxycycline, cefoperazone shubatan and amikacin have the certain effect on anti-infection therapy. Combination therapy combined with doxycycline was better treatment option for PDR infectious patients.
Conclusion: In a word, it appears to be effective for the successful therapy of PDR infections upon tetracyclines administration.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4834688 | PMC |
| http://dx.doi.org/10.1016/j.jsps.2015.01.001 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
How I diagnose and treat systemic mastocytosis with an associated hematologic neoplasm.
Blood
January 2025
Guy's & St Thomas' NHS Foundation Trust, London, United Kingdom.
Over the last decade significant advances have been made by honing in on the diagnostic evaluation and the significance of molecular profiles in patients with systemic mastocytosis (SM), non-advanced and advanced.This is reflected in the 2022 iterations of the World Health Organization Edition 5 and International Consensus Criteria classifications.The impact of targeted KIT inhibitor therapies on patients treated within global trials has demonstrated significant improvements in the prognosis and overall survival for patients, leading to a change the treatment paradigm.
View Article and Find Full Text PDFNovel insights into mechanisms and therapeutics for presbycusis.
Heliyon
January 2025
Department of Laboratory Medicine, Fujian Medical University, Fuzhou, 350122, China.
Presbycusis, also referred to as age-related hearing loss, poses a substantial burden on both individuals and society. The hallmark of presbycusis is a progressive decrease in auditory sensitivity. Irreversible hearing loss occurs due to the limited regenerative capacity of spiral neurons and peripheral cochlear hair cells (HCs).
View Article and Find Full Text PDFLong-term outcome in people who use drugs successfully treated for hepatitis C infection with glecaprevir/pibrentasvir.
J Virus Erad
December 2024
Vancouver Infectious Diseases Center, Vancouver, British Columbia, Canada.
Background: Several clinical trials, including the recently published the GRAND PLAN study from Vancouver Infectious Diseases Center (VIDC), have demonstrated the efficacy of hepatitis C (HCV) therapy among active drug users, including those facing significant addiction-related and social challenges. In the GRAND PLAN, we documented sustained virological response post-treatment Week12 (SVR12) in 108/117 (92.3 %) individuals (108/111 (mITT) or 97.
View Article and Find Full Text PDFTriglyceride-glucose index: carotid intima-media thickness and cardiovascular risk in a European population.
Cardiovasc Diabetol
January 2025
Centro E. Grossi Paoletti, Dipartimento di Scienze Farmacologiche e Biomolecolari "Rodolfo Paoletti", Università degli Studi di Milano, Milano, Italy.
Background: The triglyceride-glucose (TyG) index is now widely recognized as a marker of insulin resistance and has been linked to the development and prognosis of atherosclerotic cardiovascular diseases (ASCVD) in numerous populations, particularly in the Eastern world. Although there are fewer reports from the Western world, and they are sometimes contradictory, the absence of definitive data on the relationship between a raised TyG index and cardiovascular risk suggested the opportunity of testing this biochemical marker against a well-established vascular marker such as the carotid intima media thickness (c-IMT).
Methods: Primary prevention patients were selected from a cohort of individuals who underwent c-IMT measurement between 1984 and 2018 at the Dyslipidemia Center at the ASST Grande Ospedale Metropolitano Niguarda in Milan, Italy.
Development of Treatment Strategies for Advanced HER2-positive Gastric Cancer: Insights from Clinical Trials.
Crit Rev Oncol Hematol
January 2025
Department of Hematology and Oncology, China-Japan Union Hospital of Jilin University, Changchun, 130033, China. Electronic address:
HER2-positive gastric cancer (GC), a unique molecular subtype, has garnered significant interest in recent years. Here, we review clinical trial data on advanced HER2-positive GC from the past 15 years. Trastuzumab plus standard chemotherapy remain the first-line treatment.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!